655 related articles for article (PubMed ID: 26045046)
1. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
4. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
5. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
6. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
7. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
9. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
10. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
11. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Chen S; Dai Y; Pei XY; Grant S
Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
[TBL] [Abstract][Full Text] [Related]
12. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.
Zhang L; Lopez H; George NM; Liu X; Pang X; Luo X
Cell Death Differ; 2011 May; 18(5):864-73. PubMed ID: 21113147
[TBL] [Abstract][Full Text] [Related]
13. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
[TBL] [Abstract][Full Text] [Related]
14. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
15. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
16. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Peperzak V; Slinger E; Ter Burg J; Eldering E
Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
18. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
19. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]